[i] Paz-Ares L. G., et al. PARAMOUNT: Phase III study of maintenance pemetrexed (pem) plus best supportive care (BSC) versus placebo plus BSC immediately following induction treatment with pem plus cisplatin for advanced nonsquamous non-small cell lung cancer (NSCLC).J Clin Oncol 29: 2011 (suppl; abstr CRA7510).
[ii] World Health Organization International Agency for Research in Cancer, GLOBOCAN 2008, Section of Cancer Information, http://globocan.iarc.fr/factsheets/cance... [http://globocan.iarc.fr/factsheets/cance...], (Accessed June 20, 2012).
[iii] American Cancer Society, "What Is Non-Small Cell Lung Cancer?," February 17, 2012, American Cancer Society, http://www.cancer.org/Cancer/LungCancer-Non-SmallCell/Detail... [http://www.cancer.org/Cancer/LungCancer-Non-SmallCell/Detail...], (Accessed June 20, 2012).
[iv] American Cancer Society, "What Is Non-Small Cell Lung Cancer?," February 17, 2012, American Cancer Society, http://www.cancer.org/Cancer/LungCancer-Non-SmallCell/Detail... [http://www.cancer.org/Cancer/LungCancer-Non-SmallCell/Detail...], (Accessed June 20, 2012).
(Logo: http://photos.prnewswire.com/prnh/200312... [http://photos.prnewswire.com/prnh/200312...] )
CONTACT: Refer to: +1-317-651-4017 (Carla Cox, Lilly), +1-317-473-4368(mobile), cox_carla_l@lilly.com
Web site: http://www.LillyOncology.com/
